Host-Immune Interactions in JC Virus Reactivation and Development of Progressive Multifocal Leukoencephalopathy (PML)

Overview

Journal J Neuroimmune Pharmacol

Specialties Allergy & Immunology
Neurology
Pharmacology

Date 2019 Aug 28

PMID 31452013

Citations 5

Authors

Amir Khalili

Michael Craigie

Martina Donadoni

Ilker Kudret Sariyer

Affiliations

Soon will be listed here.

Abstract

With the advent of immunomodulatory therapies and the HIV epidemic, the impact of JC Virus (JCV) on the public health system has grown significantly due to the increased incidence of Progressive Multifocal Leukoencephalopathy (PML). Currently, there are no pharmaceutical agents targeting JCV infection for the treatment and the prevention of viral reactivation leading to the development of PML. As JCV primarily reactivates in immunocompromised patients, it is proposed that the immune system (mainly the cellular-immunity component) plays a key role in the regulation of JCV to prevent productive infection and PML development. However, the exact mechanism of JCV immune regulation and reactivation is not well understood. Likewise, the impact of host factors on JCV regulation and reactivation is another understudied area. Here we discuss the current literature on host factor-mediated and immune factor-mediated regulation of JCV gene expression with the purpose of developing a model of the factors that are bypassed during JCV reactivation, and thus are potential targets for the development of therapeutic interventions to suppress PML initiation. Graphical Abstract.

Citing Articles

Progressive Multifocal Leukoencephalopathy in a Young Medication-Noncompliant HIV Patient: A Case Report and Literature Review.

Aung N, Mamo R, Castellano G, Akbariansaravi A Cureus. 2025; 17(1):e76747.

PMID: 39897212 PMC: 11785407. DOI: 10.7759/cureus.76747.

Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis.

Rindi L, Zace D, Braccialarghe N, Massa B, Barchi V, Iannazzo R Drug Saf. 2024; 47(4):333-354.

PMID: 38321317 DOI: 10.1007/s40264-023-01383-4.

Progressive Multifocal Leukoencephalopathy in Systemic Lupus Erythematosus: A Consequence of Patient-Intrinsic or -Extrinsic Factors?.

Emmanouilidou E, Kosmara D, Papadaki E, Mastorodemos V, Constantoulakis P, Repa A J Clin Med. 2023; 12(21).

PMID: 37959410 PMC: 10647998. DOI: 10.3390/jcm12216945.

Designing a Multi-Epitope Subunit Vaccine against VP1 Major Coat Protein of JC Polyomavirus.

Kanse S, Khandelwal M, Pandey R, Khokhar M, Desai N, Kumbhar B Vaccines (Basel). 2023; 11(7).

PMID: 37514998 PMC: 10386578. DOI: 10.3390/vaccines11071182.

Progressive multifocal leukoencephalopathy associated with chemotherapy induced lymphocytopenia in solid tumors - case report of an underestimated complication.

Mayr P, Lutz M, Schmutz M, Hoeppner J, Liesche-Starnecker F, Schlegel J Front Oncol. 2022; 12:905103.

PMID: 36003787 PMC: 9394442. DOI: 10.3389/fonc.2022.905103.

References

Waggoner J, Martinu T, Palmer S . Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant. J Heart Lung Transplant. 2009; 28(4):395-8. PMC: 3727631. DOI: 10.1016/j.healun.2008.12.010. View

Berger J, Chauhan A, Galey D, Nath A . Epidemiological evidence and molecular basis of interactions between HIV and JC virus. J Neurovirol. 2001; 7(4):329-38. DOI: 10.1080/13550280152537193. View

Ranganathan P, Khalili K . The transcriptional enhancer element, kappa B, regulates promoter activity of the human neurotropic virus, JCV, in cells derived from the CNS. Nucleic Acids Res. 1993; 21(8):1959-64. PMC: 309438. DOI: 10.1093/nar/21.8.1959. View

Himedan M, Camelo-Piragua S, Mills E, Gupta A, Aburashed R, Mao-Draayer Y . Pathologic Findings of Chronic PML-IRIS in a Patient with Prolonged PML Survival Following Natalizumab Treatment. J Investig Med High Impact Case Rep. 2017; 5(3):2324709617734248. PMC: 5624358. DOI: 10.1177/2324709617734248. View

Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan R . Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol. 1993; 67(1):277-87. PMC: 237361. DOI: 10.1128/JVI.67.1.277-287.1993. View

Bacchetta F, Mathias A, Schluep M, Du Pasquier R . Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence. Mult Scler. 2017; 23(2):300-303. DOI: 10.1177/1352458516670734. View

Ault G . Activity of JC virus archetype and PML-type regulatory regions in glial cells. J Gen Virol. 1997; 78 ( Pt 1):163-9. DOI: 10.1099/0022-1317-78-1-163. View

Saribas A, White M, Safak M . Structure-based release analysis of the JC virus agnoprotein regions: A role for the hydrophilic surface of the major alpha helix domain in release. J Cell Physiol. 2017; 233(3):2343-2359. PMC: 5705473. DOI: 10.1002/jcp.26106. View

Linda H, von Heijne A, Major E, Ryschkewitsch C, Berg J, Olsson T . Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med. 2009; 361(11):1081-7. DOI: 10.1056/NEJMoa0810316. View

10.

Windpessl M, Burgstaller S, Kronbichler A, Pieringer H, Kalev O, Karrer A . Progressive Multifocal Leukoencephalopathy Following Combined Rituximab-Based Immune-Chemotherapy for Post-transplant Lymphoproliferative Disorder in a Renal Transplant Recipient: A Case Report. Transplant Proc. 2018; 50(3):881-883. DOI: 10.1016/j.transproceed.2018.01.004. View

11.

Chowdhury M, Taylor J, Tada H, Rappaport J, Wong-Staal F, Amini S . Regulation of the human neurotropic virus promoter by JCV-T antigen and HIV-1 tat protein. Oncogene. 1990; 5(12):1737-42. View

12.

Querbes W, OHara B, Williams G, Atwood W . Invasion of host cells by JC virus identifies a novel role for caveolae in endosomal sorting of noncaveolar ligands. J Virol. 2006; 80(19):9402-13. PMC: 1617268. DOI: 10.1128/JVI.01086-06. View

13.

Sikkema T, Schuiling W, Hoogendoorn M . Progressive multifocal leukoencephalopathy during treatment with rituximab and CHOP chemotherapy in a patient with a diffuse large B-cell lymphoma. BMJ Case Rep. 2013; 2013. PMC: 3604000. DOI: 10.1136/bcr-2012-008142. View

14.

Knowles W, Pipkin P, Andrews N, Vyse A, Minor P, Brown D . Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol. 2003; 71(1):115-23. DOI: 10.1002/jmv.10450. View

15.

Fournier A, Martin-Blondel G, Lechapt-Zalcman E, Dina J, Kazemi A, Verdon R . Immune Reconstitution Inflammatory Syndrome Unmasking or Worsening AIDS-Related Progressive Multifocal Leukoencephalopathy: A Literature Review. Front Immunol. 2017; 8:577. PMC: 5440580. DOI: 10.3389/fimmu.2017.00577. View

16.

Nesper J, Smith R, Kautz A, Sock E, Wegner M, Grummt F . A cell-free replication system for human polyomavirus JC DNA. J Virol. 1997; 71(10):7421-8. PMC: 192087. DOI: 10.1128/JVI.71.10.7421-7428.1997. View

17.

Ravichandran V, Sabath B, Jensen P, Houff S, Major E . Interactions between c-Jun, nuclear factor 1, and JC virus promoter sequences: implications for viral tropism. J Virol. 2006; 80(21):10506-13. PMC: 1641797. DOI: 10.1128/JVI.01355-06. View

18.

Chen N, Chang C, Gallia G, Kerr D, Johnson E, Krachmarov C . Cooperative action of cellular proteins YB-1 and Pur alpha with the tumor antigen of the human JC polyomavirus determines their interaction with the viral lytic control element. Proc Natl Acad Sci U S A. 1995; 92(4):1087-91. PMC: 42642. DOI: 10.1073/pnas.92.4.1087. View

19.

DSouza A, Wilson J, Mukherjee S, Jaiyesimi I . Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia: a report of three cases and review of the literature. Clin Lymphoma Myeloma Leuk. 2010; 10(1):E1-9. DOI: 10.3816/CLML.2010.n.009. View

20.

Cortese I, Muranski P, Enose-Akahata Y, Ha S, Smith B, Monaco M . Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy. N Engl J Med. 2019; 380(17):1597-1605. DOI: 10.1056/NEJMoa1815039. View